Approval Process for Allopathic, Biological and Biotechnological Medications in Mexico

The seven so-called "pharmerging" countries (Brazil, China, India, Indonesia, Mexico, Russia and Turkey) are expected to account for approximately 20% of the total global pharmaceutical market by 2020.¹ In particular, Mexico is becoming a key market for medicine sales. Market growth is expected to be 13%-16% per year through at least 2013.² This double-digit growth is supported by a large increase in per capita income and purchasing power of the Mexican people expected over the next decade, which is important given that 90% of pharmaceuticals are paid for out of pocket in Mexico.³